256 related articles for article (PubMed ID: 32898941)
1. Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers.
Wu Y; Chen J; Zhao L; Li Q; Zhu J; Yang H; Guo S; Xi M
Cancer Res Treat; 2021 Jan; 53(1):172-183. PubMed ID: 32898941
[TBL] [Abstract][Full Text] [Related]
2. Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Liu G; Chen T; Zhang X; Hu B; Yu J
Cancer Med; 2024 Mar; 13(5):e7075. PubMed ID: 38477511
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.
Qi WX; Wang X; Li C; Li S; Li H; Xu F; Chen J; Zhao S; Li H
Thorac Cancer; 2023 Jun; 14(17):1556-1566. PubMed ID: 37089116
[TBL] [Abstract][Full Text] [Related]
4. A nomogram to predict short-term outcome of radiotherapy or chemoradiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma.
Liang S; Li C; Gao Z; Li J; Zhao H; Yu J; Meng X
Int Immunopharmacol; 2021 Jan; 90():107178. PubMed ID: 33218939
[TBL] [Abstract][Full Text] [Related]
5. Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Chao YK; Chang HK; Tseng CK; Liu YH; Wen YW
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868287
[TBL] [Abstract][Full Text] [Related]
6. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Xi M; Zhang P; Zhang L; Yang YD; Liu SL; Li Y; Fu JH; Liu MZ
Jpn J Clin Oncol; 2017 Aug; 47(8):683-689. PubMed ID: 28453815
[TBL] [Abstract][Full Text] [Related]
7. Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy.
Wen J; Yang H; Liu MZ; Luo KJ; Liu H; Hu Y; Zhang X; Lai RC; Lin T; Wang HY; Fu JH
Ann Oncol; 2014 Sep; 25(9):1769-1774. PubMed ID: 24907633
[TBL] [Abstract][Full Text] [Related]
8. Predicting Pathological Complete Regression with Haematological Markers During Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
Lee JH; Song C; Kang SB; Lee HS; Lee KW; Kim JS
Anticancer Res; 2018 Dec; 38(12):6905-6910. PubMed ID: 30504408
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
[TBL] [Abstract][Full Text] [Related]
10. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
[TBL] [Abstract][Full Text] [Related]
11. Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism.
Li C; Lin JW; Yeh HL; Chuang CY; Chen CC
Sci Rep; 2021 Jun; 11(1):11626. PubMed ID: 34078965
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.
Liu SL; Yang H; Zhang P; Zhang L; Zhao L; Luo LL; Fu JH; Liu MZ; Xi M
Radiother Oncol; 2015 Aug; 116(2):262-8. PubMed ID: 26243678
[TBL] [Abstract][Full Text] [Related]
13. Diffusion-weighted MRI and
Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
[TBL] [Abstract][Full Text] [Related]
14. High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer.
Fang P; Jiang W; Davuluri R; Xu C; Krishnan S; Mohan R; Koong AC; Hsu CC; Lin SH
Radiother Oncol; 2018 Sep; 128(3):584-590. PubMed ID: 29530432
[TBL] [Abstract][Full Text] [Related]
15. Comparison of therapeutic outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A prospective observational cohort study.
Liu YW; Lee JY; Wang YK; Chen YH; Fang PT; Chou SH; Chen MH; Bai LY; Yen CJ; Wu MT; Wu IC
J Formos Med Assoc; 2024 Jan; 123(1):106-115. PubMed ID: 37385933
[TBL] [Abstract][Full Text] [Related]
16. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
[TBL] [Abstract][Full Text] [Related]
17. Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy.
Cheng X; Chen B; Wang S; Zhang J; Zhu J; Liu M; Liu S; Xi M
Oncologist; 2023 Aug; 28(8):e606-e616. PubMed ID: 37061835
[TBL] [Abstract][Full Text] [Related]
18. Lymphocyte-monocyte ratio as a predictive marker for pathological complete response to neoadjuvant therapy in esophageal squamous cell carcinoma.
Zhao K; Wang C; Shi F; Li M; Yu J
Transl Cancer Res; 2020 Jun; 9(6):3842-3853. PubMed ID: 35117751
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Lordick F; D'Journo XB; Cerfolio RJ; Korst RJ; Novoa NM; Swanson SJ; Brunelli A; Ismail M; Fernando HC; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J;
J Clin Oncol; 2018 Sep; 36(27):2796-2803. PubMed ID: 30089078
[TBL] [Abstract][Full Text] [Related]
20. Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma.
Qian D; Wang Y; Zhao G; Cao F; Er P; Chen X; Cheng J; Zhang W; Li X; Zhang B; Guan Y; Zhou D; Wang J; Jiang H; Yu Z; Yuan Z; Wang P; Pang Q
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):319-328. PubMed ID: 31228553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
